Reata's $450 Million Up-Front Haul Sets A Record But Remains An Outlier
By
Christopher Morrison / Email the Author / IN VIVO October 2010, Vol. 28, No. 9
Around The Industry / Word Count: 862 / Article # 2010800163
Executive Summary
In late September, Reata Pharmaceuticals Inc. dealt its Phase IIb chronic kidney disease candidate bardoxolone to Abbott Laboratories Inc., and the $450 million down payment easily dwarfs those on other deals around development-stage drug candidates, going back as far as the eye can see.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.